Engineering and project management group AMEC hiked its dividend by a fifth after beating forecasts in 2012, but warned of more modest growth this year.
The company, which works internationally in the oil & gas, mining, clean energy, environment and infrastructure markets, raised its dividend per share for the full year by 20% from 30.5p to 36.5p.
Revenue for the 12 months to December 31st totalled £4,158m, up 28% on the £3,261m recorded in 2011 and ahead of Canaccord Genuity's forecast of £4,010bn.
Underlying revenue excluding incremental procurement rose 12%, helped by a strong performance within the Natural Resources division (which accounts for over half of group revenues) which rose 20% on an underlying basis.
Reported revenues in the division surged 39% to £2,416m with good growth in both oil & gas and mining.
"A strong performance in conventional oil & gas in the UK North Sea and the Gulf of Mexico and in mining throughout the Americas was further boosted by incremental procurement (£320m) on three key projects."
Group EBITA (earnings before interest, tax and amortisation) rose 11% year-on-year from £299m to £331m, ahead of the £327m estimated by Canaccord. Adjusted earnings per share (EPS) rose 14% to 80.4p, above with the 79.7p forecast.
Operating cash flow improved by 16% year-on-year to £309m.
Chief Executive Samir Brikho said that the company made "good progress" in 2012, and remains on track to achieve its profit target of EPS of at least 100p ahead of 2015.
However, underlying revenue growth (exc. procurement) is expected to slow to a "low-to-mid single digit" rate.
The company expects a strong performance in conventional oil & gas but "more modest" growth in the clean energy and environment & infrastructure markets in the Americas.
Oil sands revenue is forecast to reduce and the company also warned of softening demand in the mining market.
Pharmaceuticals company Shire took a hit on Thursday after admitting that on a US GAAP basis its 2012 operating income fell 14 per cent as it revealed that sales of its Adderall XR product had dropped 19 per cent.
In an otherwise upbeat set of results, the company said sales of Adderall has fallen to $429m, primarily due to lower prescription volumes following the approval of a new generic version of the product in the second quarter of 2012. Reported product sales were also affected by the accounting for the settlement of the Impax Laboratories litigation.
Operating income, on a US GAAP (generally accepted accounting principles) basis, declined from $1,109m to $949m year-on-year, primarily resulting from charges to impair intangible assets for its Resolor product in
the EU ($198m) in 2012. The impairments were due to lower actual and projected performance for the product given the increasingly challenging European reimbursement environment, the group said.
Furthermore, a charge of $58m also negatively affected operating income, which related to the agreement in principle with the US government to resolve a previously disclosed civil investigation.
However, the group stressed its confidence in the year ahead and said it is in a strong position following what it described as a strong set of results.
Full year product sales rose 12% to $4,407m, with total revenues up 10% at $4,681m. In the fourth quarter product sales rose 5.0%, with total revenues also up 5.0% at $1,201m. Product sales fell 35% to $82m during the period.
Angus Russell, Chief Executive Officer, said: "It's been another strong year for Shire with 12% growth in product sales and 14% growth in non-GAAP earnings, which have driven particularly strong cash generation. While delivering strong financial results, we continue to invest in our emerging late stage R&D [research & development] pipeline.
"Our ADHD portfolio is performing very well in a growing global market and we see further growth going forward. The positive opinion received from the European regulators for Elvanse is a significant milestone and we're now preparing for country launches in some of the largest markets in Europe.
"Our late stage R&D pipeline now holds the prospect of future growth from LDX (the active ingredient in Vyvanse) in major depressive disorder, binge eating disorder and negative symptoms of schizophrenia. Our intrathecal programs are also progressing well as we plan the next clinical trials for Hunter CNS and Sanfilippo A and continue to enrol MLD patients into the ongoing Phase 1/2 trial. A phase 2b study of SPD602, our iron chelating product, is underway and headline results are expected later this year.
"Shire is in great shape, with the current business performing well, a promising pipeline of new growth opportunities, and the strategy in place to deliver an exciting future. As we look forward to the year ahead, we expect our financial results to show further growth in line with current consensus earnings expectations for 2013(1)."